Last mentioned: Feb 26, 2026
Trulieve Cannabis and MannKind reported divergent Q4 results, with Trulieve showing improved bottom-line resilience despite revenue misses, while MannKind delivered a significant revenue beat offset by an earnings-per-share shortfall. These results highlight the ongoing tension between operational scaling and profitability in the cannabis and specialty pharmaceutical sectors.
This page surfaces every story mentioning Trulieve Cannabis across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Trulieve Cannabis was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |